---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041294"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:02:47.441007+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma reports Q2 net loss $17.4M; neffy PDUFA date Sept 19, 2023

## Summary
- Cash, equivalents and short-term investments $252.2M as of June 30, 2023, funding at least three years.
- R&D expense $7.3M, G&A $13.3M, net loss $17.4M for Q2 2023.
- PDUFA target action date for neffy NDA (intranasal epinephrine) set for September 19, 2023.
- FDA Advisory Committee voted 16:6 adults, 17:5 children for favorable benefit-risk profile.
- Commercial preparations underway; hiring 115 field reps; European MAA decision expected by year end 2023.

## SEC filing metadata
- accession: 0000950170-23-041294
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/0000950170-23-041294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/spry-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041294
- JSON: https://secwatch.observer/filing/0000950170-23-041294.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041294.txt

## Key facts
- Earnings Releases
  ARS Pharmaceuticals, Inc. reported the three and six months ended June 30, 2023 results: net income Net loss was $17.4 million for the quarter ended June 30, 2023..
  - Period: the three and six months ended June 30, 2023
  - Net income: Net loss was $17.4 million for the quarter ended June 30, 2023.
  - Result: reported results
  source text: On August 10, 2023, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/0000950170-23-041294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.